Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
adenosine
Biotech
Portage launches Tarus' solid tumor portfolio into new offshoot
Over 2 years after acquiring Tarus, Portage is launching Tarus’ adenosine receptor antagonists in a standalone company helmed by a familiar leader
James Waldron
Jan 6, 2025 10:00am
Portage Biotech hints at potential closure as it halts programs
Apr 12, 2024 10:22am
Incyte scraps six R&D programs
May 2, 2023 12:48pm
Kyowa Kirin axes Parkinson's med, citing daunting future hurdles
Jul 15, 2022 3:06pm
Portage acquires adenosine receptor-focused Tarus
Jul 7, 2022 10:10am
Former Janssen US oncology chief to lead Teon Therapeutics
Mar 8, 2022 5:30am
